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purpose
Previously published guidelines are available that provide
comprehensive recommendations for detecting and prevent-
ing healthcare-associated infections. The intent of this doc-
ument is to highlight practical recommendations in a concise
format designed to assist acute care hospitals in implementing
and prioritizing their Clostridium difficile infection (CDI) pre-
vention efforts. Refer to the Society for Healthcare Epide-
miology of America/Infectious Diseases Society of America
“Compendium of Strategies to Prevent Healthcare-Associated
Infections” Executive Summary and Introduction and ac-
companying editorial for additional discussion.
section 1: rationale and statements
of concern
1. Increasing rates of CDI
C. difficile now rivals methicillin-resistant Staphylococcus au-
reus (MRSA) as the most common organism to cause health-
care-associated infections in the United States.1
a. In the United States, the proportion of hospital dis-
charges in which the patient received the International Clas-
sification of Diseases, Ninth Revision discharge diagnosis
code for CDI more than doubled between 2000 and 2003,1
and CDI rates continued to increase in 2004 and 2005 (L.
C. McDonald, MD, personal communication, July 2007).
These increases have been seen in pediatric and adult pop-
ulations, but elderly individuals have been disproportion-
ately affected.1 CDI incidence has also increased in Canada
and Europe.2-4
b. There have been numerous reports of an increase in
CDI severity.2-6
c. Most reports of increases in the incidence and severity
of CDI have been associated with the BI/NAP1/027 strain
of C. difficile.2-6 This strain produces more toxins A and B
in vitro than do many other strains of C. difficile, produces
a third toxin (binary toxin), and is highly resistant to
fluoroquinolones.
2. Outcomes associated with CDI
CDI is associated with increased lengths of hospital stay, costs,
morbidity, and mortality among adult patients. Data on the
changing epidemiology of CDI in pediatric patients are lim-
ited and are confounded by the prevalence of asymptomatic
carriage of C. difficile among children younger than 12
months of age.7,8
a. CDI increases mean length of hospital stay from 2.6
days to 4.5 days.9,10
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b. Attributable costs of inpatient CDI have been esti-
mated to be $2,470-$3,669 per episode. Attributable in-
patient costs during the 6 months after CDI diagnosis are
$5,042-$7,179.10,11 US hospital costs for CDI management
have been estimated to be $3.2 billion per year.12
c. Patients with CDI were almost twice as likely to be
discharged to a long-term care facility than were propensity
score–matched control individuals.9
d. CDI has recently been associated with an attributable
mortality rate of 6.9% at 30 days after diagnosis and 16.7%
at 1 year.3,4,9
3. Changing risk factors and possible decrease in CDI
treatment response rates
a. Fluoroquinolones, previously infrequently associated
with CDI, have been found to be one of the primary pre-
disposing antimicrobials in recent studies.3,6,13,14
i. Virtually every antibiotic has been associated with
CDI. Cephalosporins, ampicillin, and clindamycin re-
main important predisposing antibiotics.
b. Gastric acid suppression has been recognized as a risk
factor for CDI in some studies.14,15
i. Some studies suggest that the association between
gastric acid suppression and CDI are related to other
important risk factors, such as severity of illness and
age.14,16
ii. Gastric acid suppression may be an important risk
factor for CDI outside of healthcare facilities.15
c. Several studies suggest that rates of response to treat-
ment of CDI with metronidazole are declining; these stud-
ies include a randomized, prospective, blinded, and sever-
ity-stratified study that demonstrated statistically superior
rates of response to vancomycin treatment for severe dis-
ease but not for mild disease, compared with metronidazole
treatment.17-19
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1. Surveillance definitions
Definitions for CDI surveillance in the United States and
Europe have recently been published.20,21
a. In the United Kingdom, all cases of CDI in patients
older than 65 years of age have been reported to the health-
care-associated infection surveillance system for National
Health Service Acute Trusts in England since January
2004.22 Reporting for all CDI cases in patients older than
2 years of age started in April 2007.23
b. The Canadian Hospital Epidemiology Committee, a
joint initiative of the Canadian Infectious Diseases Society
and the Canadian Nosocomial Infection Surveillance Pro-
gram, used a standard definition for CDI surveillance to
track nosocomial CDI over a 4-month period in 1997 and
after 2005 in healthcare facilities across Canada24 (M. Mil-
ler, MD, personal communication, December 2007).
c. Data are lacking to determine the ideal definition for
healthcare-associated CDI. However, this is a minor lim-
itation in light of the need for a standardized surveillance
definition for CDI. The following information focuses on
the definitions for CDI surveillance in the United States
and Europe.20,21
i. A CDI case is defined as a case of diarrhea or toxic
megacolon without other known etiology that meets 1
or more of the following criteria: (1) the stool sample
yields a positive result of a laboratory assay for C. difficile
toxin A and/or B, or a toxin-producing C. difficile or-
ganism is detected in the stool sample by culture or other
means; (2) pseudomembranous colitis is seen on en-
doscopic examination or surgery; and (3) pseudomem-
branous colitis is seen on histopathological examination.
ii. Several CDI definitions are proposed, including
community-associated CDI; community-onset, health-
care facility–associated CDI; and recurrent CDI. Health-
care facilities should track at least healthcare facility–
onset, healthcare facility–associated CDI (Table 1).20,21
iii. Surveillance for CDI is limited by the use of non–
culture-based methods to diagnose CDI, such as stool
toxin assays, which have lower sensitivity than does C.
difficile stool culture.20-22,24-27
2. Identifying patients with CDI
Positive results of diarrheal stool tests for toxigenic C. difficile
or its toxins are the most common methods used to identify
patients with CDI.20-22,24
a. Positive results of diarrheal stool tests should auto-
matically be sent to infection prevention and control pro-
fessionals and to clinicians caring for the patient.
b. Only diarrheal stools should be tested for C. difficile
or its toxins. A positive result of a test for toxigenic C.
difficile and/or its toxins in a patient with diarrhea is con-
sidered to be diagnostic for CDI. However, some centers
permit C. difficile testing of nondiarrheal stools. In such
cases, review of patient records is required to ensure that
the patient has symptoms consistent with CDI.
i. Because of the high prevalence of asymptomatic
carriage of toxigenic C. difficile among infants younger
than 1 year of age, testing should be conducted only for
infants with diarrhea along with investigation of alter-
native causes of diarrhea.7,8 Detection of C. difficile toxin
should not be assumed to be causative of diarrhea in
these infants, although infants older than 6 months of
age who are colonized have been shown to have a higher
frequency of all-cause diarrhea than do noncolonized
infants.28,29
c. A minority of patients have CDI diagnosed by vi-
sualization of pseudomembranes by endoscopy and/or his-
topathologic analysis, without positive stool test results.
3. Methods for surveillance of CDI
a. Conducting CDI surveillance to determine CDI rates
provides a measure to determine the burden of CDI at a
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table 1. Clostridium difficile Infection (CDI) Surveillance Definitions
CDI case type Definition
Healthcare facility onset, healthcare facility associated Symptom onset 148 h after admission to a healthcare facility
Community onset, healthcare facility associated Symptom onset in the community or X48 h after admis-
sion, provided that symptom onset was !4 weeks after the
last discharge from a healthcare facility
Community associated Symptom onset in the community or X48 h after admis-
sion to a healthcare facility, provided that symptom onset
was 112 weeks after the last discharge from a healthcare
facility
Indeterminate onset Case does not fit any of the above criteria for an exposure
setting (eg, onset in the community 14 weeks but !12
weeks after the last discharge from a healthcare facility)
Unknown Exposure setting cannot be determined, because of a lack of
available data
Recurrent Episode occurred X8 weeks after the onset of a previous
episode, provided that CDI symptoms from the earlier
episode resolved
note. Definitions are from McDonald et al.20 and Kuijper et al.21 When laboratory-based reporting of symptoms is used, the date
and time of stool specimen collection can be used as a surrogate for symptom onset. If data on the time a patient was admitted (in
addition to date) and/or the time stool was collected for testing are not available, CDI can be considered to be healthcare facility onset
if stool is positive for toxigenic C. difficile or a C. difficile toxin after the third calendar day after hospital admission, where the first
day is the day of admission (ie, a patient admitted on Monday with stool first positive for C. difficile toxin on Thursday or later is
considered to have healthcare facility–onset CDI).
healthcare facility. These data are also used to assess the
efficacy of interventions to prevent CDI. When they are
reported back to healthcare providers and hospital admin-
istrators, CDI rates can be applied as a tool to improve
adherence to CDI preventive measures.
b. Surveillance can be performed on specific wards or
units and/or at the level of the entire healthcare facility.
c. Laboratories performing C. difficile testing should re-
port results to infection prevention and control profes-
sionals daily. The CDI rate can be expressed as the number
of CDI case patients per 10,000 patient-days.
i. This rate is calculated as follows: (number of case
patients/number of patient-days per reporting period)
# 10,000 p rate per 10,000 patient-days.19
ii. To convert the rate per 10,000 patient-days to the
rate per 1,000 patient-days, divide the rate by 10 (con-
versely, to convert a rate from 1,000 patient-days to
10,000 patient-days, multiply the rate by 10).
d. Because of a lack of published data on CDI surveil-
lance using similar case-finding methods and surveillance
definitions, specific definitions for what constitutes an
“outbreak” or “hyperendemic” rate cannot be provided at
this time.
i. An outbreak can be defined as an increase in CDI
rate in time and/or space believed to be greater than
that expected by chance alone.
ii. A hyperendemic rate can be defined as a persis-
tently elevated CDI rate compared with past rates or
compared with rates in other, similar healthcare facilities.
section 3: strategies to prevent cdi
1. Existing guidelines and recommendations
a. Published guidelines for the management of CDI are
few, and only some address CDI prevention.22,25-27
i. Most data published on CDI prevention are from
before-after studies conducted in response to outbreaks.
Often, several concomitant interventions are performed,
making it difficult to determine the relative importance
of one intervention compared with another. Before-after
studies are also limited by time-related biases that are
difficult to adjust for in the absence of a control group
or properly conducted analyses, such as interrupted time
series analysis.30,31 However, 2 recent studies have used
these techniques, demonstrating the importance of an-
timicrobial stewardship and its role in preventing
CDI.31,32
b. Less is known about the mechanisms and prevention
of C. difficile transmission, compared with other antimi-
crobial-resistant gram-positive organisms, such as MRSA
and vancomycin-resistant enterococcus (VRE). Although
these 3 organisms have many common epidemiologic char-
acteristics, C. difficile and VRE, in particular, share risk
factors for transmission.33 The major difference among
these 3 organisms is that C. difficile forms spores, whereas
the other 2 do not. The formation of spores has novel (as
yet unknown) implications for methods of hand hygiene
and environmental disinfection, because C. difficile spores
are resistant to the bactericidal effects of alcohol and most
hospital disinfectants.
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c. General strategies to prevent CDI, per previously pub-
lished guidelines,22,24-27 include the following:
i. Methods of reducing the risk of CDI if the organism
is encountered by the patient
(a) Follow antimicrobial usage restriction and
stewardship guidelines.
ii. Methods of preventing the patient from being ex-
posed to C. difficile (disinfection and barrier methods)
(a) Avoid the use of electronic thermometers; the
handles become contaminated with C. difficile.
(b) Use dedicated patient care items and equip-
ment; if items must be shared, clean and disinfect the
equipment between patients.
(c) Use full barrier precautions (gowns and gloves)
for contact with patients with CDI and for contact
with their body substances and environment (contact
precautions).
(d) Place patients with CDI in private rooms, if
available; give isolation preference to patients with
fecal incontinence if room availability is limited.
(e) Perform meticulous hand hygiene based on
Centers for Disease Control and Prevention or World
Health Organization guidelines before and after en-
tering the room of a patient with CDI, with soap and
water or an alcohol-based hand-hygiene product (in
routine settings or settings of endemicity). Perform
hand hygiene with soap and water preferentially, in-
stead of alcohol hand hygiene products, after caring
for a patient with CDI in outbreak settings or settings
of hyperendemicity. Ensure that proper hand-hygiene
techniques are used when hand washing with soap
and water is employed.34
(f) Perform environmental decontamination of
rooms housing patients with CDI, using sodium
hypochlorite (household bleach) diluted 1 : 10 with
water, in an outbreak setting or setting of hyper-
endemicity.
(g) Educate healthcare personnel and hospital ad-
ministration about the clinical features, transmission,
and epidemiology of CDI.
d. Other important principles to be aware of when car-
ing for patients with CDI include the following:22,25-27
i. Perform testing for C. difficile only on unformed
diarrheal stools (toxin testing of formed stool is strongly
discouraged).
ii. Do not give prophylactic antimicrobial CDI ther-
apy (eg, with metronidazole or vancomycin) to patients
at high risk for CDI.
iii. Do not treat or attempt to decolonize asymptom-
atic C. difficile carriers. Antimicrobial therapy is not ef-
fective for decolonization.
iv. Do not conduct repeated testing for C. difficile if
a patient has had a stool sample positive for C. difficile,
unless symptoms resolved with treatment and then re-
turned after treatment (ie, do not perform test of cure
in patients successfully treated for CDI).
2. Infrastructure requirements
a. Trained infection prevention and control personnel
i. Infection prevention and control personnel must
have knowledge about risk factors for and methods to
prevent CDI. They must also be trained in how to de-
termine when a case of CDI is healthcare associated and
how to calculate CDI rates.20,21
b. Method to identify patients with CDI
i. Infection prevention and control personnel must
be able to identify patients with CDI as soon as possible
after their condition is diagnosed. This is necessary to
ensure that patients are placed under contact precautions
in a timely fashion. These data can also be used to cal-
culate CDI rates.
c. Ability to place patients with CDI under contact
precautions
i. Contact precautions require the ability to place pa-
tients in a private room (preferably) or to cohort patients
with CDI, as well as to place materials necessary for
compliance with contact precautions (eg, gowns and
gloves) in an easily accessible space outside of the pa-
tient’s room.
ii. Place a sign indicating that the patient is under
contact precautions outside of the patient’s room.
iii. If there is a limited number of single-bed rooms,
patients with stool incontinence should preferentially be
placed in these rooms.
iv. If it is necessary to cohort patients, cohort patients
who are colonized or infected with the same organism(s)
(eg, do not cohort patients with CDI who are discordant
in their VRE or MRSA colonization status).
v. Have systems in place to facilitate communication
among infection prevention and control, admitting,
nursing, and housekeeping departments and develop
contingency plans for conditions of limited bed
availability.
d. Provide educational materials for patients, family
members, and healthcare personnel that include explana-
tions of CDI, why contact precautions are necessary, and
the importance of hand hygiene.
e. Provide adequate resources and training for house-
keeping personnel to ensure proper cleaning of rooms.
3. Initiating a CDI prevention program
a. Pilot test the intervention in 1 patient care location
to assess efficacy.
i. Perform CDI surveillance to determine locations
where CDI rates are highest.
ii. Initiate the prevention program where there is a
high concentration of patients at risk for CDI, such as
an intensive care unit or an oncology ward.
iii. Start in 1 patient care location.
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table 2. Strength of Recommendation and Quality of Evidence
Category/grade Definition
Strength of recommendation
A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation
Quality of evidence
I Evidence from x1 properly randomized, controlled trial
II Evidence from x1 well-designed clinical trial, without
randomization; from cohort or case-control analytic
studies (preferably from 11 center); from multiple
time series; or from dramatic results from uncontrolled
experiments
III Evidence from opinions of respected authorities, based
on clinical experience, descriptive studies, or reports of
expert committees
note. Adapted from the Canadian Task Force on the Periodic Health Examination.35
(a) Identify opportunities to improve the system
for identifying patients with CDI.
(b) Identify opportunities to improve the process
for placing patients with CDI under contact precau-
tions and to minimize problems for family members,
visitors, and healthcare personnel.
iv. Obtain the support of hospital administration and
local physician and nursing leadership before starting
the program.
b. Use process and outcome measures to determine
whether the intervention is effective.
c. Replicate the CDI infection prevention and control
program in other patient care areas when it is determined
that the systems developed are effective.
section 4: recommendations for
implementing prevention and
monitoring strategies
Recommendations for preventing and monitoring CDI are
summarized in the following section. They are designed to
assist acute care hospitals in prioritizing and implementing
their CDI prevention efforts. Criteria for grading the strength
of recommendation and quality of evidence are described in
Table 2.
I. Basic practices for prevention and monitoring of CDI:
recommended for all acute care hospitals
A. Components of a CDI prevention program
1. Use contact precautions for infected patients, with a
single-patient room preferred (A-II for hand hygiene, A-I for
gloves, B-III for gowns, and B-III for single-patient
room).22,25-27
a. Place patients with CDI under contact precautions to
help reduce patient-to-patient spread of the organism.
i. Place patients in private rooms when available.
ii. Don gown and gloves on entry to the patient’s
room.
(a) Gloves should be changed immediately if vis-
ibly soiled and after touching or handling surfaces or
materials contaminated with feces.
iii. Remove gown and gloves before exiting the room.
iv. Conduct Centers for Disease Control and Preven-
tion– or World Health Organization–compliant hand
hygiene on exiting the patient’s room.
v. Cohorting patients with CDI is acceptable when
single, private rooms are not available.
(a) Place patients with stool incontinence prefer-
entially in private rooms.
(b) Do not cohort patients who have discordant
status of infection or colonization with other epide-
miologically important organisms (eg, VRE and
MRSA).
(c) Remove gowns and gloves and perform hand
hygiene when moving from one patient to another.
b. Ensure that adequate supplies for contact precautions
are readily available.
i. Management leaders are responsible to ensure that
necessary barrier-equipment supplies (eg, gowns and
gloves) and hand-hygiene products are readily available.
ii. Assign responsibility for monitoring the availabil-
ity and restocking of supplies to specific healthcare
personnel.
c. Criteria for discontinuing contact precautions
i. The Centers for Disease Control and Prevention
currently recommends contact precautions for the du-
ration of illness when caring for patients with CDI.36
Some experts recommend continuing contact precau-
tions for at least 48 hours after diarrhea resolves. Areas
of controversy include the following:
(a) Asymptomatically colonized patients (includ-
ing, in many cases, those successfully treated for CDI)
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continue to shed C. difficile spores, but the number
of spores and degree of contamination is not as great
as for patients with active CDI. There are currently
no data to support isolation of these asymptomatic
patients.37-39
(b) Prolonging the duration of contact isolation for
patients with CDI is recommended when CDI is not
effectively controlled by the use of basic practices (see
below: II. Special Approaches for the Prevention of
CDI). Similarly, there are no data to indicate the ef-
ficacy of this practice at this time.
2. Ensure cleaning and disinfection of equipment and the
environment (B-III for equipment and B-II for the en-
vironment).
a. C. difficile spores contaminate the environment in
which patients are housed and the equipment used to care
for them.26,27,37-39 This includes the following:
i. Furnishings in the room, including over-bed tables,
bed rails, furniture, sinks, floors, commodes, and toilets
ii. Patient care equipment that directly touches pa-
tients, such as thermometers, stethoscopes, and blood
pressure cuffs
iii. “High-touch” (ie, frequently touched) surfaces,
such as door knobs and intravenous fluid pumps
b. C. difficile appears to contaminate very few surfaces
outside patient rooms.37
c. Contaminated surfaces and equipment are potential
reservoirs for transmission of C. difficile.
i. Recent guidelines have outlined environmental
disinfection protocols.40 There are no US Environmen-
tal Protection Agency–registered products specific for
inactivating C. difficile spores. Data are conflicting as
to whether inactivation of spores is necessary to prevent
C. difficile transmission, especially in a setting of
endemicity.
ii. Facilities should consider using a 1 : 10 dilution of
sodium hypochlorite (household bleach) for environ-
mental disinfection in outbreak settings and settings of
hyperendemicity in conjunction with other infection
prevention and control measures (see below: II. Special
Approaches for the Prevention of CDI). The bleach so-
lution should have a contact time of at least 10 minutes.41
d. Develop and implement protocols for disinfection of
equipment and the environment.
i. On a routine basis, assess adherence to protocols
and the adequacy of cleaning.
ii. Assess the adequacy of cleaning before changing
to a new cleaning product (eg, bleach). If cleaning is not
adequate, address this before changing products (see be-
low: II. Special Approaches for the Prevention of CDI).
iii. Because of the high turnover of housekeeping per-
sonnel, educate personnel on proper cleaning technique
frequently. Ensure that education is provided in the per-
sonnel’s native language.
e. Dedicate noncritical patient care items, such as blood
pressure cuffs, stethoscopes, and thermometers, to a single
patient with CDI.
i. When this is not possible, ensure adequate cleaning
and disinfection of shared items between patient en-
counters. Ensure that the manufacturers’ recommen-
dations for contact time of disinfectants are followed.
3. Implement a laboratory-based alert system to provide
immediate notification to infection prevention and control
personnel and clinical personnel about patients with newly
diagnosed CDI (B-III).
a. To place patients with CDI under contact precautions
in a timely manner, it is important that an alert system be
developed between the laboratory and both infection pre-
vention and control personnel and clinical personnel caring
for the patient. This alert system should immediately notify
infection prevention and control and clinical personnel
when a patient has newly diagnosed CDI.
b. There are a variety of methods by which this infor-
mation can be transmitted, but some options include fax
alerts, phone call and pager alerts, or automated secure
electronic alerts.
i. The alert system should not rely on fax transmis-
sions alone, because there may be delays from the time
the transmission is received to the time it is seen by an
appropriate healthcare provider.
c. Alert patient care areas of positive test results im-
mediately, so that these patients can be placed under con-
tact precautions.
d. When a patient has active CDI, communicate the CDI
status when transferring the patient to another healthcare
facility, so that appropriate precautions can be imple-
mented at the accepting facility.
4. Conduct CDI surveillance and analyze and report CDI
data (B-III).
a. At a minimum, calculate healthcare facility–onset,
healthcare facility–associated CDI rates at the unit/ward
and organizational levels (Table 1).20,21
b. Provide CDI data and other CDI prevention process
and outcome measures to key stakeholders, including
senior leadership, physicians, nursing staff, and other
clinicians.
c. Provide the process and outcome measures outlined
in the “Performance Measures” section below to appro-
priate hospital staff and administrators on a regular basis.
The frequency with which these data are provided will
depend on the hospital’s existing reporting structure and
the type of data collected. These data can be added to
routine quality assessment and performance improvement
reports.
5. Educate healthcare personnel, housekeeping personnel,
and hospital administration about CDI (B-III).
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a. Include risk factors, routes of transmission, local
CDI epidemiology, patient outcomes and treatment, and
prevention measures (including Centers for Disease Con-
trol and Prevention and World Health Organization rec-
ommendations regarding proper hand hygiene, contact
precautions, and management of multidrug-resistant
organisms).34,42,43
6. Educate patients and their families about CDI, as ap-
propriate (B-III).
a. Although often not considered part of a program to
reduce transmission of multidrug-resistant organisms,
proper education may help to alleviate patient fears re-
garding being placed in isolation.44
i. Include information about anticipated questions:
general information about CDI, colonization versus in-
fection, the hospital’s CDI prevention program, the com-
ponents of and rationale for contact precautions, and
the risk of transmission to family and visitors while in
the hospital and after discharge. Helpful materials might
include patient education sheets in appropriate lan-
guage(s) and the use of patient education channels, Web
sites, or VHS tapes and DVDs.
7. Measure compliance with Centers for Disease Control
and Prevention or World Health Organization hand-hygiene
and contact precaution recommendations (B-III).
a. Patient-to-patient transmission of C. difficile is
thought to occur primarily through transient contamina-
tion of the hands of healthcare personnel with spores.
b. Glove use when caring for patients with CDI or
touching surfaces in their rooms has been shown to be
effective at preventing the transmission of C. difficile.
c. Hand-hygiene practices in compliance with Centers
for Disease Control and Prevention or World Health Or-
ganization guidelines are critical to C. difficile control and
prevention. Evidence-based recommendations for imple-
mentation and assessment of hand-hygiene programs in
healthcare settings have been published.34
i. Area of controversy: There are concerns regarding
reliance on alcohol-based hand-hygiene products, be-
cause alcohol is not sporicidal. Conversely, hand washing
with soap and water is associated with much lower com-
pliance. In settings where CDI is endemic, it appears the
potential decrease in efficacy of alcohol-based hand-hy-
giene products for removing spores, compared with
hand washing, may be offset by the increase in hand-
hygiene adherence with alcohol-based hand-hygiene
products, if contact precautions are followed (ie, if gloves
and gowns are worn) when caring for patients with
CDI.45
B. Accountability
1. The hospital’s chief executive officer and senior man-
agement are responsible for ensuring that the healthcare sys-
tem supports an infection prevention and control program
that effectively prevents CDI and the transmission of epi-
demiologically significant pathogens.
2. Senior management is accountable for ensuring that an
adequate number of trained personnel are assigned to the
infection prevention and control program.
3. Senior management is accountable for ensuring that
healthcare personnel, including licensed and nonlicensed per-
sonnel, are competent to perform their job responsibilities.
4. Direct healthcare providers (such as physicians, nurses,
aides, and therapists) and ancillary personnel (such as house-
keeping and equipment-processing personnel) are responsible
for ensuring that appropriate infection prevention and con-
trol practices are used at all times (including hand hygiene,
standard and isolation precautions, and cleaning and disin-
fection of equipment and the environment).
5. Hospital and unit leaders are responsible for holding
personnel accountable for their actions.
6. The person who manages the infection prevention and
control program is responsible for ensuring that an active
program to identify CDI is implemented, that data on CDI
are analyzed and regularly provided to those who can use the
information to improve the quality of care (eg, unit staff,
clinicians, and hospital administrators), and that evidence-
based practices are incorporated into the program.
7. Personnel responsible for healthcare personnel and pa-
tient education are accountable for ensuring that appropriate
training and educational programs to prevent CDI are de-
veloped and provided to personnel, patients, and families.
8. Personnel from the infection prevention and control
program, the laboratory, and information technology de-
partments are responsible for ensuring that systems are in
place to support the surveillance program.
II. Special approaches for the prevention of CDI
Perform a CDI risk assessment. These special approaches are
recommended for use in locations and/or populations within
the hospital that have unacceptably high CDI rates despite
implementation of the basic CDI prevention strategies listed
above.
There are several unresolved issues regarding CDI preven-
tion. This is apparent when reviewing the rankings of each
recommendation on the basis of the quality of the data to
support it. As a result, implementation of the recommen-
dations beyond the basic practices to prevent CDI should be
individualized at each healthcare facility. One may consider
a “tiered” approach in which recommendations are instituted
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individually or in groups; additional “tiers” are added if CDI
rates do not improve, with implementation of basic practices
as the first tier.
A. Approaches to minimize C. difficile transmission by health-
care personnel
1. Intensify the assessment of compliance with process
measures (B-III).
a. Contact precautions: Gowns and gloves should be
worn by all healthcare personnel who enter the rooms of
patients under contact precautions.
b. Hand hygiene: Hand hygiene should be performed
on entry and exit from patient rooms. When hand washing
is performed, determine whether proper techniques are
being used (eg, hand washing for at least 15 seconds).34
c. If hand-hygiene compliance or techniques are not
adequate, conduct interventions to improve hand-hygiene
compliance and techniques.
2. Perform hand hygiene with soap and water as the pre-
ferred method before exiting the room of a patient with CDI
(B-III).
a. Ensure proper hand-hygiene technique when using
soap and water.34
b. Be aware that hand-hygiene adherence may decrease
when soap and water is the preferred method.
i. Additional education may be necessary to remind
healthcare workers that alcohol-based hand-hygiene
products are superior to hand washing for non–spore-
forming organisms (eg, MRSA).
3. Place patients with diarrhea under contact precautions
while C. difficile test results are pending (B-III).
a. To decrease transmission, it is essential to place symp-
tomatic patients under contact precautions as soon as di-
arrhea symptoms are recognized.
b. If the results of C. difficile testing are negative, the
patient has a low pretest probability of CDI, and the
patient is continent of stool, contact precautions can be
discontinued.
i. Because of concerns about the low sensitivity of
enzyme immunoassays, clinical suspicion of CDI should
outweigh negative test results for patients with a high
pretest probability of having CDI.
4. Prolong the duration of contact precautions after the
patient becomes asymptomatic until hospital discharge (B-
III).
a. Patients may still shed C. difficile in their stool after
diarrhea resolves.46-48
B. Approaches to minimize CDI transmission from the
environment
1. Assess the adequacy of room cleaning (B-III).
a. If room cleaning practices are deemed to be inade-
quate, focus on improving room cleaning techniques.
b. Important issues to address include proper dilution
of cleaning products, adequacy of cleaning technique,
cleaning “high-touch” surfaces, frequency of changing rags/
mop water, and moving from “clean” areas to “dirty” areas.
i. Create a checklist based on cleaning protocols and
perform observations to monitor cleaning practice.
ii. Environmental culture for C. difficile is difficult to
perform and requires specialized media; therefore, it is
not routinely recommended.49
c. Consider environmental decontamination with so-
dium hypochlorite if room cleaning is deemed to be ad-
equate but there is ongoing CDI transmission (see below).
2. Use sodium hypochlorite (bleach)–containing cleaning
agents for environmental cleaning. Implement a system to
coordinate with the housekeeping department if it is deter-
mined that sodium hypochlorite is needed for environmental
disinfection (B-II).
a. Area of controversy: Data on the ability of diluted
sodium hypochlorite or other sporicidal agents used for
environmental decontamination to control CDI have not
been consistent. However, a beneficial effect has been re-
ported when bleach has been used in outbreak settings or
settings of hyperendemicity, typically in conjunction with
other enhanced CDI control measures.40,50-53
b. When diluted sodium hypochlorite is instituted for
environmental decontamination, it is necessary to coor-
dinate activities with housekeeping staff.
i. Clinical, infection prevention and control, and
housekeeping staff will need to determine the location,
type, and frequency of diluted sodium hypochlorite use.
For instance:
(a) All rooms, only rooms of patients with CDI,
or outside of patient rooms?
(b) Daily cleaning or terminal cleaning only when
the patient is discharged or transferred?
c. When diluted sodium hypochlorite is used, it is im-
portant to address the following issues:
i. Avoid toxicity to patients and staff and damage to
equipment and the environment from bleach use. So-
dium hypochlorite can be corrosive and irritating to
patients, housekeeping staff, and other healthcare
personnel.
ii. The sodium hypochlorite solution must be mixed
fresh daily.
d. When sodium hypochlorite will be used only in the
rooms of patients with CDI, a system will need to be created
to identify these patients to the housekeeping staff.
C. Approaches to reduce the risk of CDI acquisition
1. Initiate an antimicrobial stewardship program (A-
II).22,25-27,32,54,55
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a. Assess the appropriateness of antimicrobial prescrib-
ing practices.
i. Restrict antimicrobials that are strongly associated
with CDI and promote appropriate antimicrobial use.
III. Approaches that should not be considered a routine
part of CDI prevention
1. Do not test patients without signs or symptoms of CDI
for C. difficile (B-II).
a. C. difficile toxin tests have been studied in patients
with symptoms of CDI and a high pretest probability of
having CDI. A positive C. difficile toxin test result for a
patient without symptoms has a high probability of being
a false-positive result.
i. Only stool culture for C. difficile has been confirmed
to identify patients with asymptomatic C. difficile col-
onization. The sensitivity, specificity, and negative and
positive prediction values of antigen and toxin assays
are unknown for asymptomatic patients.
b. Obtaining stool specimens requires nursing time to
collect and laboratory technician time to perform the test
and report results.
c. A positive toxin test result for an asymptomatic pa-
tient may result in the initiation of unnecessary treatment
for CDI, which may increase the patient’s risk of developing
CDI in the future.56
d. Do not place patients with asymptomatic C. difficile
colonization under contact precautions.
i. Area of controversy: Previous research has demon-
strated that asymptomatically colonized patients can be a
source of transmission of C. difficile and that patients can
remain colonized after symptoms cease.38,39,47-49 However,
asymptomatically colonized patients are less likely than
symptomatic patients to contaminate their surrounding
environment or serve as a source of transmission. In
some settings, the duration of contact precautions can
be extended if there is concern that asymptomatically
colonized patients represent a significant source of po-
tential C. difficile exposure.
e. Do not attempt to decolonize asymptomatic patients,
because this has not been effective and may increase the
patient’s risk of developing CDI in the future.56
2. Do not repeat C. difficile testing at the end of successful
therapy for a patient recently treated for CDI (B-III).
a. A positive test result may result in unnecessary pro-
longation of contact precautions and CDI treatment.
i. In some settings, contact precautions may be ex-
tended until hospital discharge after symptom resolution
(see above). However, there are insufficient data to rec-
ommend extending the duration of contact precautions
on the basis of whether C. difficile or its toxins can be
detected in the patient’s stool.
b. A positive test result at the end of therapy does not
predict who will develop a recurrence or relapse.48
c. Repeated C. difficile testing does not provide any use-
ful clinical information but requires nursing time to collect
the specimen and laboratory technician time to perform
the test and report results.48
IV. Unresolved issues
1. Use of gowns and gloves by family members and other
visitors
a. The utility of requiring family members and other
visitors to wear gowns and gloves to prevent C. difficile
transmission is unknown.57 The risk that family members
and other visitors will transmit C. difficile between patients
is likely to be related to the degree of contact the visitor
has with the patient and the patient’s environment, whether
the visitor performs hand hygiene, and the degree of in-
teraction the visitor has with other patients. At a minimum,
family members and other visitors should be instructed to
perform hand hygiene whenever entering or leaving the
patient’s room.
2. Standing orders or nurse-driven protocols to test all
patients with diarrhea for C. difficile
a. Nurses frequently know, before the treating physician
does, when a patient has diarrhea
3. Admitting-based alert systems that notify infection pre-
vention and control and clinical personnel about readmitted
or transferred patients with a history of CDI
a. This information can be integrated into a comput-
erized database used during admission and registration or
a separate electronic or paper-based database.
i. If an alert system is implemented, patients with a
history of CDI should be placed under contact precau-
tions if they are readmitted only if they have symptoms
consistent with CDI at admission. Asymptomatic pa-
tients with a history of CDI do not require contact
precautions.
ii. The duration that the alert should remain active
is unknown. Nearly all cases of recurrent CDI occur
within 90 days after the last episode. On the basis of
this fact, it is reasonable to discontinue the alert 90 days
after the last episode of CDI. However, healthcare fa-
cilities may not be aware of recurrent episodes of CDI
that are diagnosed and managed in outpatient settings,
so an arbitrary cutoff based on the last known episode
of CDI may inadvertently remove patients with ongoing
recurrent CDI.
4. Ongoing assessment of CDI knowledge and intensified
CDI education among healthcare personnel
a. Re-educate staff if prior CDI training occurred more
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than 12 months earlier or if overall knowledge is deemed
to be inadequate.
i. Include housekeeping personnel in educational
efforts.
5. Restricting the use of gastric acid suppressants14,16
section 5: performance measures
I. Internal reporting
These performance measures are intended to support internal
hospital quality improvement efforts and do not necessarily
address external reporting needs. The process and outcome
measures suggested here are derived from published guide-
lines, other relevant literature, and the opinions of the au-
thors. Report process and outcome measures to senior hos-
pital leadership, nursing leadership, and clinicians who care
for patients at risk for CDI.
A. Process measures
1. Compliance with hand-hygiene guidelines
a. Preferred measure for hand-hygiene compliance
i. Numerator: number of observed proper hand-hy-
giene episodes performed by healthcare personnel.
ii. Denominator: total number of observed oppor-
tunities for hand hygiene.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
b. If hand hygiene with soap and water is the preferred
method of hand hygiene when caring for patients with CDI,
also assess proper hand washing techniques (minimum du-
ration of 15 seconds).
i. Numerator: number of proper hand washing epi-
sodes with proper technique.
ii. Denominator: total number of hand washing ep-
isodes observed.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
2. Compliance with contact precautions
a. Preferred measure of contact precautions compliance
i. Numerator: number of observed patient care epi-
sodes in which contact precautions are appropriately
implemented.
ii. Denominator: number of observed patient care ep-
isodes in which contact precautions are indicated.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
3. Compliance with environmental cleaning
a. One specific measure of compliance for use in all
hospitals cannot be recommended. However, many hos-
pitals use checklists and environmental rounds to assess
the cleaning process and cleanliness of equipment and the
environment (see above).
B. Outcome measures
Perform ongoing measurement of the incidence density of
CDI to permit longitudinal assessment of the processes of
care.
1. CDI rates should be calculated according to the recently
published recommendations and as described above.20,22
a. See Table 1 for case definitions.
i. Numerator: number of CDI cases in the population
being monitored (the specific cases included in the nu-
merator depends on the definition used; see Table 1).
ii. Denominator: total number of patient-days in the
population being monitored.
iii. Multiply by 10,000 so that measure is expressed
as number of cases per 10,000 patient-days.
b. To convert the rate per 10,000 patient-days to 1,000
patient-days, divide the rate by 10 (conversely, to convert
a rate from 1,000 patient-days to 10,000 patient-days, mul-
tiply the rate by 10).
II. External reporting
There are many challenges in providing useful information
to consumers and other stakeholders while preventing un-
intended adverse consequences of public reporting of health-
care-associated infections.58 Recommendations for public re-
porting of healthcare-associated infections have been
provided by the Hospital Infection Control Practices Advisory
Committee,59 the Healthcare-Associated Infection Working
Group of the Joint Public Policy Committee,60 and the Na-
tional Quality Forum.61
Given the absence until recently of standardized CDI sur-
veillance definitions and the difficulties in ascertaining the
specific time and location of C. difficile acquisition, specific
recommendations for external reporting of CDI rates cannot
be made at this time.
A. State and local requirements
1. Hospitals in states that have mandatory reporting re-
quirements for CDI must collect and report the data required
by the state.
2. For information on local requirements, check with your
state or local health department.
B. External quality initiatives
1. Hospitals that participate in external quality initiatives
must collect and report the data if required by the initiative.
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